Apoptosis in autoimmune diseases

Internal Medicine

Volumn 40, Issue 4, 2001, Pages 275-284

  Eguchi, Katsumi ^a  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Autoimmune thyroid disease; Fas Fas ligand pathway; Immune privileged site; Rheumatoid arthritis; Systemic lupus erythematosus

Indexed keywords

AUTOANTIBODY;

ANIMAL; APOPTOSIS; AUTOIMMUNE DISEASE; AUTOIMMUNE THYROIDITIS; HUMAN; IMMUNOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

ANIMALS; APOPTOSIS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; T-LYMPHOCYTES; THYROIDITIS, AUTOIMMUNE;

EID: 0035318470     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.40.275     Document Type: Review

References (100)

1. Nagata S. Apoptosis by death factor. Cell 88: 355-365, 1997.
2. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 367: 1456-1462, 1995.
3. Green DR. Apoptotic pathways: the roads to ruin. Cell 94: 695-698, 1998.
4. Green DR. Apoptotic pathways: paper wraps stone blunts scissors. Cell 102: 1-4, 2000.
5. Utz PJ, Anderson P. Posttranslational protein modifications, apoptosis and the bypass of tolerance to autoantigens. Arthritis Rheum 41: 1152-1160, 1998.
6. Itoh N, Yonehara S, Ishii A, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66: 233-243, 1991.
7. Itoh N, Nagata S. A novel protein domain required for apoptosis: mutational analysis of human Fas antigen. J Biol Chem 268: 10932-10937, 1993.
8. Mountz JD, Wu J, Cheng J, Zhou T. Autoimmune disease: a problem of defective apoptosis. Arthritis Rheum 37: 1415-1420, 1994.
9. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM. FADD, a novel death domain-containing protein interacts with the death domain of Fas and initiates apoptosis. Cell 81: 505-512, 1995.
10. Muzio M, Chinnaiyan AM, Kischkel FC, et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/ APO-1) death-inducing signaling complex. Cell 85: 817-827, 1996.
11. Kischkel FC, Hellbardt S, Behrmann I, et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 14: 5579-5588, 1995.
12. Hu S, Vincenz C, Ni J, Gentz R, Dixit VM. I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1-and CD95-induced apoptosis. J Biol Chem 272: 17255-17257, 1997.
13. Irmler M, Thome M, Hahne M, et al. Inhibition of death receptor signals by cellular FLIP. Nature 388: 190-195, 1997.
14. Hsu H, Xiong J, Goeddel DV. The TNF receptor-1 associated protein TRADD signals cell death and NF-κB activation. Cell 81: 495-504, 1995.
15. Marsters SA, Sheridan JP, Donahue CJ, et al. Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-κB. Curr Biol 6: 1669-1676, 1996
16. Marsters SA, Sheridan JP, Pitti RM, Brush J, Goddard A, Ashkenazi A. Identification of a ligand for the death-domain-containing receptor Apo-3. Curr Biol 8: 525-528, 1998.
17. Golstein P. Cell death: TRAIL and its receptors. Curr Biol 7: R750-R753, 1997.
18. Griffith TS, Lynch DH. TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol 10: 559-563, 1998.
19. Mc Cubrey JA, May WS, Duronio V, Mufson A. Serine/threonine phosphorylation in cytokine signal transduction. Leukemia 14: 9-21, 2000.
20. Cross TG, Scheel-Toellner D, Heriquez NV, Deacon E, Salmon M, Lord JM. Serine/Threonine protein kinases and apoptosis. Exp Cell Res 256: 34-41, 2000.
21. Kumar S. ICE-like proteases in apoptosis. Trend Biochem Sci 20: 198-202, 1995.
22. Salveson GS, Dixit VM. Caspases: intracellular signaling by proteolysis. Cell 91: 443-446, 1997.
23. Wallach D, Boldin M, Varfolomeev E, Beyaert R, Vandenabeele P, Fiers W. Cell death induction by receptors of the TNF family: towards a molecular understanding. FEBS Lett 410: 96-106, 1997.
24. Muzio M, Salvesen GS, Dixit VM. FLICE induced apoptosis in a cell-free system. J Biol Chem 272: 2952-2956, 1997.
25. Scaffidi C, Schmitz I, Zha J, Korsmeyer SJ, Krammer PH, Peter ME. Differential modulation of apoptosis sensitivity in CD95 type I and type II cells. J Biol Chem 274: 22532-22538, 1999.
26. Yang J, Liu X, Bhalla K, et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275: 1129-1132, 1997.
27. Kharbanda S, Pandey P, Schofield L, et al. Role for Bcl-xL as an inhibitor of cytosolic cytochrome c accumulation in DNA damage-induced apoptosis. Proc Natl Acad Sci USA 94: 6939-6942, 1997.
28. Cain K, Bratton SB, Langlais C, et al. Apaf-1 oligomerizes into biologically active approximately 700-kDa and inactive approximately 1. 4-MDa apoptosome complexes. J Biol Chem 275: 6067-6070, 2000.
29. Eskes R, Desagher S, Antonsson B, Martinou JC. Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane. Mol Cell Biol 20: 929-935, 2000.
30. Moriishi K, Huang DC, Cory S, Adams JM. Bcl-2 family members do not inhibit apoptosis by binding the caspase activator Apaf-1. Proc Natl Acad Sci USA 96: 9683-9688, 1999.
31. Deveraux QL, Roy N, Stennicke HR, et al. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J 17: 2215-2223, 1998.
32. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102: 33-42, 2000.
33. Verhagen AM, Ekert PG, Pakusch M, et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 102: 43-53, 2000.
34. Kawakami A, Eguchi K, Matsuoka N, et al. Thyroid-stimulating hormone inhibits Fas antigen-mediated apoptosis of human thyrocytes in vitro. Endocrinology 137: 3163-3169, 1996.
35. Kawakami A, Eguchi K, Matsuoka N, et al. Modulation of Fas-mediated apoptosis of human thyroid epithelial cells by IgG from patients with Grave's disease (GD) and idiopathic myxoedema. Clin Exp Immunol 110: 434-439, 1997.
36. + T cell-mediated cytotoxicity toward thyrocytes: the importance of Fas/Fas ligand interaction inducing apoptosis of thyrocytes and the inhibitory effect of thyroid stimulating hormone. Lab Invest 80: 471-484, 2000.
37. Bretz JD, Rymaszewski M, Arscott PL, et al. TRAIL death pathway expression and induction in thyroid follicular cells. J Biol Chem 274: 23627-23632, 1999.
38. Giordano C, Stassi G, De Maria R, et al. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science 275: 960-963, 1997.
39. Sera N, Kawakami A, Nakashima T, et al. Fas/FasL mediated apoptosis of thyrocytes in Graves' disease. Clin Exp Immunol, accepted, 2000.
40. Xerri LD, Devilard E, Hassoun J, Mawas C, Birg F. Fas ligand is not only expressed in immune privileged human organs but is also coexpressed with Fas in various epithelial tissues. Mol Pathol 50: 87-91, 1997.
41. Bretz JD, Arscott PL, Myc A, Baker JR Jr, et al. Inflammatory cytokine regulation of Fas-mediated apoptosis in thyroid follicular cells. J Biol Chem 274: 25433-25438, 1999.
42. Hammond LJ, Lowdell MW, Cerrano PG, Goode AW, Bottazzo GF, Marakian R. Analysis of apoptosis in relation of tissue destruction associated with Hashimoto's autoimmune thyroiditis. J Pathol 182: 138-144, 1997.
43. Tamura M, Kimura H, Koji T, et al. Role of apoptosis of thyrocytes in a rat model of goiter: a possible involvement of Fas system. Endocrinology 139: 3646-3653, 1998.
44. Kawabe Y, Eguchi K, Shimomura C, et al. Interleukin-1 production and action in thyroid tissue. J Clin Endocrinol Metab 68: 1174-1183, 1989.
45. Mihara S, Suzuki N, Wakisaka S, et al. Effects of thyroid hormones on apoptotic cell death of human lymphocytes. J Clin Endocrinol Metab 84: 1378-1385, 1999.
46. Von Muhlen CA, Tan EM. Autoantibodies in the diagnosis of syotemic rheumatic diseases. Semin Arthritis Rheum 24: 323-358, 1995.
47. Amoura Z, Piette JC, Bach JF, Koutouzov S. The key role of nucleosomes in lupus. Arthritis Rheum 42: 833-843, 1999.
48. Emlen W, Niebur J, Kadera R. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol 152: 3685-3692, 1994.
49. Firestein GS, Yeo M, Zvaifler NJ. Apoptosis in rheumatoid arthritis synovium. J Clin Invest 96: 1631-1638, 1995.
50. Asahara H, Hasunuma T, Kobata T, et al. Expression of Fas antigen and fas ligand in the rheumatoid synovial tissue. Clin Immunol Immunopathol 81: 27-34, 1996.
51. Sekine C, Yagita H, Kobata T, Hasunuma T, Nishioka K, Okumura K. Fas-mediated stimulation induces IL-8 sercretion by rheumatoid arthritis synoviocytes independently of CPP32-mediated apoptosis. Biochem Biophys Res Commun 228: 14-20, 1996
52. Kawakami A, Eguchi K, Matsuoka N, et al. Inhibition of Fas antigen-mediated apoptosis of rheumatoid synovial cells in vitro by transforming growth factor β1. Arthritis Rheum 39: 1267-1276, 1996.
53. Nakajima T, Aono H, Hasunuma T, et al. Apoptosis and functional Fas antigen in rheumatoid arthritis synoviocytes. Arthritis Rheum 38: 485-491, 1995.
54. Perlman H, Georganas C, Pagliari LJ, Koch AE, Haines K, Pope RM. Bcl-2 expression in synovial fibroblasts is essential for maintaining mitochondrial homeostasis and cell viability. J Immunol 164: 5227-5235, 2000.
55. Handel ML, McMorrow LB, Gravallese EM. Nuclear factor-κB in rheumatoid synovium. Arthritis Rheum 38: 1762-1770, 1995.
56. Marok R, Winyard PG, Coumbe A, et al. Activation of the transcription factor nuclear factor-κB in human inflamed synovial tissue. Arthritis Rheum 39: 583-591, 1996.
57. Yamasaki S, Kawakami A, Nakashima T, et al. Importance of NF-κB in rheumatoid synovial tissue: in situ NF-κB expression and in vitro study using cultured synovial cells. Ann Rheum Dis, accepted.
58. Kawakami A, Nakashima T, Sakai H, et al. Regulation of synovial cell apoptosis by proteasome inhibitor. Arthritis Rheum 42: 2440-2448, 1999.
59. Kobayashi H, Okamoto K, Kobata T, et al. Differential regulation of Fas-mediated apoptosis of rheumatoid synoviocytes by tumor necrosis factor α and basic fibroblast growth factor is associated with the expression of apoptosis-related molecules. Arthritis Rheum 43: 1106-1114, 2000.
60. Tsuboi M, Eguchi K, Kawakami A, et al. Fas antigen expression on synovial cells was down-regulated by interleukin 1β. Biochem Biophys Res Commun 218: 280-285, 1996.
61. Beg AA, Baltimore D. An essential role for NF-κB in preventing TNFα-induced cell death. Science 274: 782-784, 1996.
62. Kobayashi T, Okamoto K, Kobata T, Hasunuma T, Sumida T, Nishioka K. Tumor necrosis factor α regulation of the Fas-mediated apoptosis signaling pathway in synovial cells. Arthritis Rheum 42: 519-526, 1999.
63. Sumida T, Hoa TT, Asahara H, Hasunuma T, Nishioka K. T cell receptor of Fas-sensitive T cells in rheumatoid synovium. J Immunol 158: 1965-1970, 1997.
64. Sugiyama M, Tsukazaki T, Yonekura A, Matsuzaki S, Yamashita S, Iwasaki K. Localisation of apoptosis and expression of apoptosis-related proteins in the synovium of patients with rheumatoid arthritis. Ann Rheum Dis 55: 442-449, 1996.
65. Salmon M, Scheel-Toellner D, Huissoon AP, et al. Inhibition of T cell apoptosis in the rheumatoid synovium. J Clin Invest 99: 439-446, 1997.
66. Reparon-Schuijt CC, van Esch WJ, van Kooten C, et al. Regulation of synovial B cell survival in rheumatoid arthritis by vascular cell adhesion molecule 1 (CD106) expressed on fibroblast-like synoviocytes. Arthritis Rheum 43: 1115-1121, 2000.
67. Osame M, Matsumoto M, Usuku K, et al. Chronic progressive myelopathy associated with elevated antibodies to human T-lymphotropic virus type I and adult T-cell leukemia-like cells. Ann Neurol 21: 117-122, 1987.
68. Eguchi K, Matsuoka N, Ida H, et al. Primary Sjögren's syndrome with antibodies to HTLV-I: clinical and laboratory features. Ann Rheum Dis 51: 769-776, 1992.
69. Terada K, Katamine S, Eguchi K, et al. Prevalence of serum and salivary antibodies to HTLV-I in Sjögren's syndrome. Lancet 344: 1116-1119, 1994.
70. Eguchi K, Origuchi T, Takashima H, Iwata K, Katamine S, Nagataki S. High seroporevalence of anti-HTLV-I antibody in rheumatoid arthritis. Arthritis Rheum 39: 463-466, 1996.
71. Nakamura H, Eguchi K, Nakamura T, et al. High prevalence of Sjögren's syndrome in patients with HTLV-I associated myelopathy. Ann Rheum Dis 56: 167-172, 1997.
72. Kawakami A, Nakashima T, Sakai H, et al. Inhibition of caspase cascade by HTLV-I tax through induction of NF-κB nuclear translocation. Blood 94: 3847-3854, 1999.
73. Iwakura Y, Tosu M, Yoshida E, et al. Induction of inflammatory arthopathy resembling rheumatoid arthritis in mice transgenic for HTLV-I. Science 253: 1026-1028, 1991.
74. Kishi S, Saijo S, Arai M, et al. Resistance to Fas-mediated apoptosis of peripheral T cells in human T lymphocyte virus type I (HTLV-I) transgenic mice with autoimmune arthopathy. J Exp Med 186: 57-64, 1997.
75. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356: 314-317, 1992.
76. Takahashi T, Tanaka M, Brannan CI, et al. Generalized lymphopro-liferative disease in mice, caused by a point mutation in the Fas ligand. Cell 76: 969-976, 1994.
77. White E, Sabbatini P, Debbas M, Wold WS, Kusher DI, Gooding LR. The 19-kilodalton adenovirus E1B transforming protein inhibits programmed cell death and prevents cytolysis by tumor necrosis factor alpha. Mol Cell Biol 12: 2570-2580, 1992.
78. Henderson S, Huen D, Rowe M, Dawson C, Johnson G, Rickinson A. Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. Proc Natl Acad Sci USA 90: 8479-8483, 1993.
79. Green JE, Hinrichs SH, Vogel J, Jay G. Exocrinopathy resembling Sjögren's syndrome in HTLV-I tax transgenic mice. Nature 341: 72-74, 1989.
80. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21: 115-137, 2000.
81. Weinstein RS, Manolagas SC. Apoptosis and osteoporosis. Am J Med 108: 153-164, 2000.
82. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids: potential mechanisms of their deleterious effects on bone. J Clin Invest 102: 274-282, 1998.
83. Nakao H, Eguchi K, Kawakami A, et al. Phenotypic characterization of lymphocytes infiltrating synovial tissue from patients with rheumatoid arthritis: analysis of lymphocytes isolated from minced synovial tissue by dual immunofluorescent staining. J Rheumatol 17: 142-148, 1990.
84. Tanaka Y, Morimoto I, Nakano Y, et al. Osteoblasts are regulated by the cellular adhesion through ICAM-1 and VCAM-1. J Bone Miner Res 10: 1462-1469, 1995.
85. Kawakami A, Nakashima T, Tsuboi M, et al. Insulin-like growth factor I stimulates proliferation and Fas-mediated apoptosis of human osteoblasts. Biochem Biophys Res Commun 247: 46-51, 1998.
86. Kawakami A, Eguchi K, Matsuoka N, et al. Fas and Fas ligand interaction is necessary for human osteoblast apoptosis. J Bone Miner Res 12: 1637-1646, 1997.
87. Tsuboi M, Kawakami A, Nakashima T, et al. Tumor necrosis factor-α and interleukin-1β increase the Fas-mediated apoptosis of human osteoblasts. J Lab Clin Med 134: 222-231, 1999.
88. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of tumor necrosis factor receptor and ligand families. Endocr Rev 20: 345-357, 1999.
89. Lacey DL, Timms E, Tan H-L, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165-176, 1998.
90. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95: 3597-3602, 1998.
91. Nakagawa N, Kinosaki M, Yamaguchi K, et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 253: 395-400, 1998.
92. Jimi E, Akiyama S, Tsurukai T, et al. Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. J Immunol 163: 434-442, 1999.
93. Nakashima T, Kobayashi Y, Yamasaki S, et al. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-κB ligand, RANKL: modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun 275: 768-775, 2000.
94. Hughes DE, Dai A, Tiffee JC, Li HH, Mundy GR, Boyce BF. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-β. Nat Med 2: 1132-1136, 1996.
95. Luckman SP, Coxon FP, Ebetino FH, Russell RG, Rogers MJ. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res 13: 1668-1678, 1998.
96. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonate and calcitonin. J Clin Invest 104: 1363-1374, 1999.
97. 2 on osteoblast apoptosis: vitamin K2 inhibits apoptotic cell death of human osteoblasts induced by Fas, proteasome inhibitor, etoposide, and staurosporine. J Lab Clin Med 136: 181-193, 2000.
98. L. Transplantation 68: 1018-1023, 1999.
99. Ichinose Y, Eguchi K, Migita K, et al. Apoptosis induction in synovial fibroblasts bt ceramide: in vitro and in vivo effects. J Lab Clin Med 131: 410-416, 1998.
100. Migita K, Honda S, Yamasaki S, et al. Regulation of rheumatoid synovial cell growth by ceramide. Biochem Biophys Res Commun 269: 70-75, 2000.